JP2009539348A5 - - Google Patents

Download PDF

Info

Publication number
JP2009539348A5
JP2009539348A5 JP2009513297A JP2009513297A JP2009539348A5 JP 2009539348 A5 JP2009539348 A5 JP 2009539348A5 JP 2009513297 A JP2009513297 A JP 2009513297A JP 2009513297 A JP2009513297 A JP 2009513297A JP 2009539348 A5 JP2009539348 A5 JP 2009539348A5
Authority
JP
Japan
Prior art keywords
seq
sequence
cdr
antibody
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009513297A
Other languages
English (en)
Japanese (ja)
Other versions
JP4560582B2 (ja
JP2009539348A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/012950 external-priority patent/WO2007143098A2/en
Publication of JP2009539348A publication Critical patent/JP2009539348A/ja
Publication of JP2009539348A5 publication Critical patent/JP2009539348A5/ja
Application granted granted Critical
Publication of JP4560582B2 publication Critical patent/JP4560582B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009513297A 2006-06-02 2007-06-01 肝細胞成長因子(hgf)結合蛋白質 Expired - Fee Related JP4560582B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US86046106P 2006-11-21 2006-11-21
PCT/US2007/012950 WO2007143098A2 (en) 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010167648A Division JP5528246B2 (ja) 2006-06-02 2010-07-26 肝細胞成長因子(hgf)結合蛋白質

Publications (3)

Publication Number Publication Date
JP2009539348A JP2009539348A (ja) 2009-11-19
JP2009539348A5 true JP2009539348A5 (enExample) 2010-08-05
JP4560582B2 JP4560582B2 (ja) 2010-10-13

Family

ID=38802082

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009513297A Expired - Fee Related JP4560582B2 (ja) 2006-06-02 2007-06-01 肝細胞成長因子(hgf)結合蛋白質
JP2010167648A Expired - Fee Related JP5528246B2 (ja) 2006-06-02 2010-07-26 肝細胞成長因子(hgf)結合蛋白質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010167648A Expired - Fee Related JP5528246B2 (ja) 2006-06-02 2010-07-26 肝細胞成長因子(hgf)結合蛋白質

Country Status (15)

Country Link
US (5) US7659378B2 (enExample)
EP (2) EP2029627B1 (enExample)
JP (2) JP4560582B2 (enExample)
KR (1) KR101196184B1 (enExample)
AR (1) AR061170A1 (enExample)
AT (1) ATE533787T1 (enExample)
AU (1) AU2007254853B2 (enExample)
BR (1) BRPI0712223A2 (enExample)
CA (1) CA2654019A1 (enExample)
ES (1) ES2378097T3 (enExample)
IL (2) IL195038A0 (enExample)
MX (1) MX2008015138A (enExample)
NO (1) NO20085422L (enExample)
NZ (1) NZ573819A (enExample)
WO (1) WO2007143098A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007254853B2 (en) * 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
AU2007254942B2 (en) 2006-06-02 2011-10-27 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
JP5931336B2 (ja) 2007-07-02 2016-06-08 オンコメッド ファーマシューティカルズ インコーポレイテッド がんを処置および診断するための組成物および方法
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CN102076355B (zh) 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US8101725B2 (en) 2008-05-29 2012-01-24 Galaxy Biotech, Llc Monoclonal antibodies to basic fibroblast growth factor
SG191639A1 (en) * 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2009256246B2 (en) 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
AU2009268585C1 (en) * 2008-07-08 2014-10-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
MX2011000117A (es) 2008-07-10 2011-02-25 Toray Industries Composicion farmaceutica para tratamiento y prevencion de cancer.
DK2842573T3 (en) 2008-11-07 2017-10-30 Galaxy Biotech Llc Monoclonal antibodies to fibroblast growth factor receptor 2
CA2743775A1 (en) * 2008-11-12 2010-05-20 Schering Corporation .beta.gi-igg intron for enhanced anti-igf1r expression
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
TW201119673A (en) * 2009-09-01 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32948A (es) * 2009-10-15 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
CN103459422A (zh) 2010-11-24 2013-12-18 葛兰素集团有限公司 靶向hgf的多特异性抗原结合蛋白
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
WO2013102042A2 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CA2878868A1 (en) 2012-07-13 2014-01-16 Austin L. Gurney Rspo3 binding agents and uses thereof
HK1212359A1 (en) 2012-11-01 2016-06-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
CN105246915A (zh) * 2013-03-14 2016-01-13 奥尔德生物制药公司 Hgf抗体及含有其的组合物
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
WO2016025797A1 (en) * 2014-08-15 2016-02-18 Oncomed Pharmaceuticals, Inc. Rspo1 binding agents and uses thereof
EP3193935A4 (en) 2014-09-16 2018-03-21 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
EP3209769B1 (en) 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
WO2016065245A1 (en) 2014-10-24 2016-04-28 Incept, Llc Extra luminal scaffold
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
WO2016205566A1 (en) * 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
CA3039910A1 (en) * 2016-03-28 2017-10-05 The Regents Of The University Of California Anti-ryk antibodies and methods of using the same
NL2017267B1 (en) * 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
BR112019025583A2 (pt) 2017-06-05 2020-06-16 Janssen Biotech, Inc. Anticorpos multiespecíficos geneticamente modificados e outras proteínas multiméricas com mutações assimétricas na região ch2-ch3
CA3067351A1 (en) * 2017-06-15 2018-12-20 Nai-Kong Cheung Anti-l1-cam antibodies and uses thereof
CN118667812A (zh) 2017-12-06 2024-09-20 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
WO2019217450A1 (en) * 2018-05-08 2019-11-14 Rhode Island Hospital Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
JP2022525703A (ja) * 2019-03-20 2022-05-18 ジャベリン・オンコロジー・インコーポレイテッド 抗adam12抗体およびキメラ抗原受容体、ならびにそれを含む組成物および方法
EP4013869A1 (en) 2019-08-12 2022-06-22 InteRNA Technologies B.V. New treatments involving mirna-193a
CN115461461A (zh) 2020-02-28 2022-12-09 因特尔纳技术有限公司 用于促进免疫原性细胞死亡的miRNA-193a
JP7748962B2 (ja) 2020-03-27 2025-10-03 アビディティー バイオサイエンシーズ,インク. 筋ジストロフィーを処置するための組成物および方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
US7459536B1 (en) * 1999-11-09 2008-12-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HGF-SF monoclonal antibody combinations
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
RS53476B (sr) 2003-07-18 2014-12-31 Amgen Fremont Inc. Sredstva za specifično vezivanje faktora rasta hepatocita
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Hgf의 중화가능 에피토프 및 이에 결합하는 중화 항체
JP2008545753A (ja) 2005-06-02 2008-12-18 ギャラクシー バイオテック, エルエルシー 抗体で脳腫瘍を処置する方法
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
AU2007254853B2 (en) * 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
AU2007254942B2 (en) 2006-06-02 2011-10-27 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
KR100829972B1 (ko) * 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-hgf/sf 인간화 항체 및 이의 제조방법

Similar Documents

Publication Publication Date Title
JP2009539348A5 (enExample)
JP2009225799A5 (enExample)
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
JP2010246565A5 (enExample)
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2008112004A3 (en) ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
RU2531523C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2010526028A5 (enExample)
NZ585622A (en) Hepatitis c virus antibodies
WO2005016111A3 (en) Antibodies directed to parathyroid hormone (PTH) and uses thereof
JP2010511388A5 (enExample)
JP2023093753A5 (enExample)
WO2006130458A3 (en) Antibodies directed to cd20 and uses thereof
JP2010535205A5 (enExample)
WO2006113643A3 (en) High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
JP2018504105A5 (enExample)
NO20074867L (no) Antistoffer mot CCR5 og anvendelser derav
WO2005069970A3 (en) Antibody specificity transfer using minimal essential binding determinants
JP2013506428A5 (enExample)
WO2007070432A3 (en) Binding proteins specific for insulin-like growth factors and uses thereof
NZ601342A (en) Antibodies that bind il-4 and/or il-13 and their uses
RU2015151505A (ru) Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1)
JP2015504421A5 (enExample)
JP2017512759A5 (enExample)